Coloplast Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kristian Villumsen

Chief Executive Officer (CEO)

DKK 21.4m

Compensación total

Porcentaje del salario del CEO	54.2%
Permanencia del CEO	4yrs
Participación del CEO	0.04%
Permanencia media de la dirección	4.7yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kristian Villumsen en comparación con los beneficios de Coloplast?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b
Jun 30 2017	n/a	n/a	DKK 3b
Mar 31 2017	n/a	n/a	DKK 3b
Dec 31 2016	n/a	n/a	DKK 3b
Sep 30 2016	DKK 10m	DKK 6m	DKK 3b

Compensación vs. Mercado: La compensación total de Kristian($USD3.06M) está por debajo de la media de empresas de tamaño similar en el mercado Swiss ($USD5.86M).

Compensación vs. Ingresos: La compensación de Kristian ha sido consistente con los resultados de la empresa en el último año.

CEO

Kristian Villumsen (52 yo)

4yrs

Permanencia

DKK 21,400,000

Compensación

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kristian Villumsen	President & CEO	4yrs	DKK 21.40m	0.043% DKK 10.5m
Anders Lonning-Skovgaard	Executive VP & CFO	8.4yrs	DKK 10.80m	sin datos
Allan Rasmussen	Executive Vice President of Global Operations	8.4yrs	DKK 9.60m	0.00015% DKK 36.8k
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 9.00m	sin datos
Paul Marcun	Executive Vice President of Growth	3.9yrs	DKK 11.00m	sin datos
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000030% DKK 7.4k
Ellen Bjurgert	Vice President of Investor Relations	6.2yrs	sin datos	sin datos
Dennis Kaysen	Director of Corporate Communications	no data	sin datos	sin datos
Dorthe Ronnau	Senior Vice President of People & Culture	less than a year	sin datos	sin datos
Alain Morvan	Senior Vice President of Sales Europe	10.7yrs	sin datos	sin datos
Rasmus Møller	Senior Vice President of Wound & Skin Care	2.3yrs	sin datos	sin datos
Manu Varma	Senior Vice President of Chronic Care - North America	4.7yrs	sin datos	sin datos

4.7yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 020259063 se considera experimentado (4.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Barfod	Senior Controller & Employees Representative Director	16.9yrs	DKK 450.00k	0.000030% DKK 7.4k
Carsten Hellmann	Independent Director	5yrs	DKK 690.00k	0.0028% DKK 694.2k
Lars Rasmussen	Chairman of the Board	4yrs	DKK 1.84m	0.098% DKK 24.0m
Niels Louis-Hansen	Deputy Chairman	54.9yrs	DKK 938.00k	21.14% DKK 5.2b
Marianne Wiinholt	Independent Director	2yrs	DKK 880.00k	0.00024% DKK 58.9k
Jette Nygaard-Andersen	Independent Director	7yrs	DKK 600.00k	sin datos
Nikolaj Gundersen	Employees Representative Director	4.9yrs	DKK 450.00k	0% DKK 0
Roland Pedersen	Employees Representative Director	4.9yrs	DKK 450.00k	0.00070% DKK 171.7k
Annette Bruls	Independent Director	less than a year	DKK 497.00k	sin datos

4.9yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 020259063 se considera experimentada (4.9 años de antigüedad promedio).

Coloplast Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Coloplast Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Recent updates

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Less than half of directors are independent

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

First quarter 2021 earnings released

Revenue beats expectations

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad